Selective PGT Inhibitor Compounds for Low Off-Target Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prostaglandin transporter (PGT) inhibitors are non-specific, leading to off-target effects, and there is a need for targeted and efficacious inhibitors to manage conditions associated with prostaglandin levels, increase systemic levels of prostaglandin E2, and enhance prostacyclin signaling pathways.
Innovation Solution
Development of specific compounds of Formula 1 and their pharmaceutically acceptable salts, which inhibit PGT with low-nM inhibition and excellent selectivity, modulating prostaglandin signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If known PGT inhibitors (OAT inhibitors like bromcresol green and bromosulfophthalein, or COX2 inhibitors like indomethacin and ibuprofen) are used, then PGT inhibition is achieved, but off-target effects occur and specificity is poor
Solution Approach 1:
The patent modifies the chemical structure of PGT inhibitors by changing molecular parameters - specifically incorporating a pyridine ring with specific substituents (R1-R4 groups) at defined positions to create compounds of Formula 1. This structural parameter change enables selective binding to PGT while avoiding off-target effects, achieving both high reliability of inhibition and specificity.
Solution Approach 2:
The invention creates composite molecular structures combining specific functional groups (pyridine core with carboxylic acid or ester substituents) to achieve dual functionality - PGT inhibition and reduced off-target effects. The composite structure integrates multiple chemical features that work together for selective inhibition.
2Adaptability or versatility
If non-specific PGT inhibitors are used, then broad PGT inhibition is achieved, but targeted efficacy for specific conditions (PAH, hyperinflammation) is compromised
Solution Approach 1:
The patent applies local quality by creating inhibitors with specific molecular features (pyridine ring with particular substituents) that are locally optimized for PGT binding. The specific structural motifs at defined positions provide targeted efficacy for conditions like PAH and hyperinflammation while maintaining broad PGT inhibition capability.
Data Source
AI summary
The disclosure provides compounds of Formula 1, and the pharmaceutically acceptable salts thereof. The variables in Formula 1, e.g. X1-X5, A1, A2, and R1-R4 are described herein. Such compounds are useful as prostaglandin transport (PGT) inhibitors. The disclosure further includes pharmaceutical compositions comprising a compound of Formula 1 or salt thereof and methods of using compounds of Formula 1 and salts thereof to treat diseases and disorders mediated, at least in part, by prostaglandin levels or cyclooxygenase activity. Such diseases and disorders include painful and inflammatory conditions.